Quoin Pharmaceuticals Ltd
QNRX6.860USD
+0.040+0.59%
Cierre 08/04, 16:00（ET）Cotizaciones retrasadas 15 min
141.22MCap. mercado
PérdidaP/E TTM
Más Datos de Quoin Pharmaceuticals Ltd Compañía
Quoin Pharmaceuticals Ltd, former Cellect Biotechnology Ltd, is an Israel-based specialty pharmaceutical company, focused on developing and commercializing therapeutic products that treat rare and orphan diseases. The Company’s first lead product is QRX003, a once daily, topical lotion comprised of a broad-spectrum serine protease inhibitor, formulated with the proprietary Invisicare technology, to treat Netherton Syndrome. The product going to be developed for other rare dermatological diseases including Peeling Skin Syndrome, SAM Syndrome, and Palmoplantar Keratoderma. Quoin is also developing QRX004 as a potential treatment for Dystrophic Epidermolysis Bullosa, and QRX006 as a potential therapy for an, as of yet, undisclosed rare skin disease.
Información de la empresa
Símbolo de cotizaciónQNRX
Nombre de la empresaQuoin Pharmaceuticals Ltd
Fecha de salida a bolsaNov 01, 1989
Director ejecutivoDr. Michael Myers, Ph.D.
Número de empleados3
Tipo de seguridadDepository Receipt
Fin del año fiscalNov 01
Dirección23 Hata'as Street
CiudadKFAR SABA
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísIsrael
Código postal44425
Teléfono97299741444
Sitio Webhttps://quoinpharma.com/
Símbolo de cotizaciónQNRX
Fecha de salida a bolsaNov 01, 1989
Director ejecutivoDr. Michael Myers, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
17.22K
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. Eyal Leibovitz
Mr. Eyal Leibovitz
Chief Financial Officer
Chief Financial Officer
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Mr. Jonathan Burgin, CPA
Mr. Jonathan Burgin, CPA
Independent External Director
Independent External Director
--
--
Mr. Yali Sheffi
Mr. Yali Sheffi
Independent External Director
Independent External Director
--
--
Mr. Guy Sapir
Mr. Guy Sapir
Internal Auditor
Internal Auditor
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Michael Myers, Ph.D.
Dr. Michael Myers, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
17.22K
--
Dr. Amos Ofer
Dr. Amos Ofer
Chief Operating Officer, Vice President
Chief Operating Officer, Vice President
--
--
Dr. Amotz Nehushtan
Dr. Amotz Nehushtan
Vice President - Research & Development & Product Development
Vice President - Research & Development & Product Development
--
--
Mr. Eyal Leibovitz
Mr. Eyal Leibovitz
Chief Financial Officer
Chief Financial Officer
--
--
Mr. David L. Braun
Mr. David L. Braun
Independent Director
Independent Director
--
--
Ms. Ronit Biran
Ms. Ronit Biran
Independent Director
Independent Director
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 26 de jul
Actualizado: sáb., 26 de jul
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Myers (Michael)
2.93%
Carter (Denise P)
2.93%
UBS Financial Services, Inc.
1.07%
Dunn (Gordon)
0.73%
Culverwell (Anthony James)
0.49%
Other
91.86%
Accionistas
Accionistas
Proporción
Myers (Michael)
2.93%
Carter (Denise P)
2.93%
UBS Financial Services, Inc.
1.07%
Dunn (Gordon)
0.73%
Culverwell (Anthony James)
0.49%
Other
91.86%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
7.08%
Investment Advisor
1.44%
Investment Advisor/Hedge Fund
0.16%
Other
91.32%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
33
51.05K
8.68%
-35.06K
2025Q1
35
78.22K
9.34%
-7.90K
2024Q4
33
2.93M
35.77%
+2.56M
2024Q3
29
288.95K
5.54%
-93.09K
2024Q2
30
301.96K
12.37%
-13.30K
2024Q1
28
276.13K
11.96%
+132.88K
2023Q4
28
104.03K
10.54%
-33.36K
2023Q3
27
83.72K
8.48%
+6.49K
2023Q2
28
91.62K
18.66%
+37.20K
2023Q1
30
101.74K
19.68%
+59.45K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Myers (Michael)
17.22K
2.93%
--
--
Mar 10, 2025
Carter (Denise P)
17.22K
2.93%
+1.00
+0.01%
Mar 10, 2025
UBS Financial Services, Inc.
6.27K
1.07%
+6.13K
+4507.35%
Mar 31, 2025
Dunn (Gordon)
4.32K
0.73%
--
--
Mar 10, 2025
Culverwell (Anthony James)
2.87K
0.49%
+2.86K
+31744.44%
Mar 10, 2025
Rhumbline Advisers Ltd. Partnership
1.19K
0.2%
+504.00
+73.15%
Mar 31, 2025
Raymond James Financial Services Advisors, Inc.
718.00
0.12%
--
--
Mar 31, 2025
Lido Advisors, LLC
672.00
0.11%
+672.00
--
Mar 31, 2025
Susquehanna International Group, LLP
320.00
0.05%
+320.00
--
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Mar 26, 2025
Merger
20<1
Jun 28, 2023
Merger
12<1
Jun 28, 2023
Merger
12<1
Jun 28, 2023
Merger
12<1
Jun 28, 2023
Merger
12<1
Jul 29, 2022
Merger
12.5<1
Fecha
Tipo
Relación
Mar 26, 2025
Merger
20<1
Jun 28, 2023
Merger
12<1
Jun 28, 2023
Merger
12<1
Jun 28, 2023
Merger
12<1
Jun 28, 2023
Merger
12<1
Jul 29, 2022
Merger
12.5<1
Jul 29, 2022
Merger
12.5<1
Jul 29, 2022
Merger
12.5<1
Jul 29, 2022
Merger
12.5<1
Sep 23, 2021
Merger
4<1
Ver más
